Design Therapeutics (DSGN) Revenue & Revenue Breakdown
Design Therapeutics Revenue Highlights
00
Design Therapeutics Revenue by Period
Design Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $226.00 | -72.90% |
2019-12-31 | $834.00 | - |
Design Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $838.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $33.00K | 65.00% |
2020-09-30 | $20.00K | -35.48% |
2020-06-30 | $31.00K | -78.17% |
2020-03-31 | $142.00K | - |
Design Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
IMCR | Immunocore | $249.43M | $75.40M |
ADCT | ADC Therapeutics SA | $69.56M | $17.41M |
AADI | Aadi Bioscience | $24.35M | $7.21M |
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
ALVR | AlloVir | - | - |
ALXO | ALX Oncology | - | - |
CCCC | C4 Therapeutics | - | - |
GRCL | Gracell Bio | - | - |
GRPH | LENZ Therapeutics | - | - |
ERAS | Erasca | - | - |
NLTX | Neurogene | - | - |
ACHL | Achilles Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |